PAH and pulmonary arterial hypertension: Phenylalanine hydroxylase–deficient (PAH-deficient) phenylketonuria (PKU) is the paradigm for treatable inborn errors of metabolism, motivating development of the first prospective newborn screening programs (1, 2).